Lee M. Ellis
李·埃利斯
MD
Professor, Departments of Surgical Oncology and Molecular and Cellular Oncology外科肿瘤学与分子细胞肿瘤学系教授
👥Biography 个人简介
Lee Ellis is a surgeon-scientist at MD Anderson whose translational research defined mechanisms of bevacizumab activity and resistance in colorectal cancer. His group elucidated how tumors evade VEGF blockade and identified alternative proangiogenic pathways, guiding the next generation of antiangiogenic drug combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Anti-VEGF Resistance in Colorectal Cancer
Identified upregulation of alternative angiogenic factors (FGF, angiopoietins) as key escape mechanisms following bevacizumab treatment, establishing rationale for multi-target antiangiogenic strategies.
Bevacizumab Clinical Translation
Contributed foundational work translating VEGF biology into surgical oncology practice, improving perioperative bevacizumab protocols and defining optimal integration with colorectal surgery.
Representative Works 代表性著作
VEGF-targeted therapy: mechanisms of anti-tumour activity
Nature Reviews Cancer (2008)
Comprehensive mechanistic review of how bevacizumab and VEGFR TKIs exert antitumor effects and how tumors develop adaptive resistance.
Resistance to anti-VEGF therapy in colorectal cancer: the role of alternative angiogenic pathways
Clinical Cancer Research (2012)
Identified specific molecular mechanisms by which colorectal cancers escape bevacizumab blockade through activation of FGF and PDGF signaling.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 李·埃利斯 的研究动态
Follow Lee M. Ellis's research updates
留下邮箱，当我们发布与 Lee M. Ellis（The University of Texas MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment